Indaptus Halts Decoy20, Pivots to Strategic Alternatives with $11.6M Cash
INDP is trading near its 52-week low of $0.92 (9.8% above the low) on light trading volume (0.3× avg).
Summary
Indaptus Therapeutics reported Q2 2026 results showing a strategic pivot away from its Decoy20 program, with no active clinical trials and a going concern warning. Cash runway extends to Q2 2027 after recent financings.
Key Events · Earnings and Guidance · INDP
-
Decoy20 Program Discontinued
Company halted enrollment in its combination study and has no participants remaining in any Decoy20 clinical study. No new clinical trials are planned.
-
Strategic Alternatives Evaluation
Indaptus is evaluating a Post-Investment Transaction involving investment in or acquisition of an operating business, while also exploring sleep-related research initiatives.
-
Cash Runway Extended to Q2 2027
Cash and equivalents of $7.55M plus $4.0M in short-term CDs as of June 30, 2026, provide liquidity through June 30, 2027, but going concern doubt remains.
-
Massive Dilution from Preferred Conversion
All 1,000,000 preferred shares converted into 111,000,000 common shares in March 2026, increasing outstanding shares from 2.17M to 133.24M.
Analysis · INDP · Life Sciences
Indaptus has discontinued its lead clinical program Decoy20 and now has no active clinical trials. The company is evaluating strategic alternatives including acquisitions or investments in operating businesses. Cash of $7.55M plus $4.0M in CDs provides runway through Q2 2027, but the going concern warning remains. The company also repriced warrants to $1.75 and converted all preferred stock, massively diluting existing shareholders.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INDP was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $115.5M. The 52-week trading range was $0.92 to $8.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.